A Conversation with Dr. Iman Osman
Dr. Osman’s group at NYU has successfully utilized the Sengenics protein microarray to identify autoantibody signatures predictive of both response (recurrence) and adverse outcomes from immune checkpoint inhibition for treatment of melanoma. She discussed her work with us and the benefits of functional protein microarrays to her research.
You can read the interview HERE.
